Tamoxifen is commonly used in the management of patients with breast cancer. Clinical trials of tamoxifen involving over 75,000 patients demonstrate an improved recurrence-free and overall survival benefit in both pre- and post-menopausal women. Large-scale trials also are evaluating the role of tamoxifen as a chemopreventive agent in women considered to be at high risk for developing breast cancer based on family history. Endometrial cancer is an uncommon complication of tamoxifen therapy. Since the majority of these cancers will be detected at an early stage when they are highly curable, however, the overall benefit of tamoxifen treatment in breast cancer patients outweighs this risk. All women receiving tamoxifen who have a uterus should undergo regular gynecologic examinations.
Get full access to this article
View all access options for this article.
References
1.
KillackeyM.A., HakesT.B., PierceV.K.Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep.1985; 69: 237–238.
2.
HardellL.Tamoxifen as risk factor for carcinoma of corpus uteri. Lancet.1988; 2: 563.
3.
Tamoxifen and the uterus and endometrium. Lancet.1989; 1: 375–376.
4.
FornanderT., RutqvistL.E., CedermarkB.Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet.1989; 1: 117–120.
5.
AtlanteG., PozziM., VincenzoniC.Four case reports presenting new acquisitions on the association between breast and endometrial cancer. Gynecol Oncol.1990; 37: 378–380.
6.
MathewA., ChabonA.B., KabakowB.Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. N Y State J Med.1990; 90: 207–208.
7.
MalfetanoJ.H.Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol.1990; 39: 82–84.
8.
MagriplesU., NaftolinF., SchwartzP.E.High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol.1993; 11: 485–490.
9.
LahtiE., BlancoG., KauppilaA.Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol.1993; 81: 660–664.
10.
SeoudM.A., JohnsonJ., WeedJ.C.Jr. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol.1993; 82: 165–169.
11.
van LeeuwenF.E., BenraadtJ., CoeberghJ.W.Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet.1994; 343: 448–452.
12.
FisherB., CostantinoJ.P., RedmondC.K.Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst.1994; 86: 527–537.
13.
BarakatR.R., WongG., CurtinJ.P.Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol.1994; 55: 164–168.
14.
SilvaE.G., TornosC.S., Follen-MitchellM.Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol.1994; 13: 248–258.
15.
RutqvistL.E., JohanssonH., SignomklaoT.Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst.1995; 87: 645–651.
16.
SatyaswaroopP.G., ZainoR.J., MortelR.Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res.1984; 44: 4006–4010.
17.
GottardisM.M., RobinsonS.P., SatyaswaroopP.G.Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res.1988; 48: 812–815.
18.
BoccardoF., BruzziP., RubagottiA.Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology.1981; 38: 281–285.
19.
WolfD.M., JordanV.C.Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol.1992; 45: 118–128.
20.
ElwoodJ.M., BoyesD.A.Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol.1980; 10: 173–187.
21.
FornanderT., HellstromA.C., MobergerB.Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst.1993; 85: 1850–1855.
22.
GalD., KopelS., BashevkinM.Oncologic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol.1991; 42: 120–123.
23.
GibsonL.E., BarakatR.R., VenkatramanE.S.Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Cancer J Sci Am.1996. In press.
24.
BarakatR.R., GilewskiT.A., SaigoP.E.The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: an interim analysis of a prospective study. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A778.
25.
CohenI., RosenD.J., TepperR.Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med.1993; 12: 275–280.
26.
KedarR.P., BourneT.H., PowlesT.J.Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet.1994; 343: 1318–1321.
27.
GoldsteinS.R.Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol.1994; 170: 447–451.
28.
HanX.L., LiehrJ.G.Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res.1992; 52: 1360–1363.
29.
WhiteI.N., de MatteisF., DaviesA.Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis.1992; 13: 2197–2203.
30.
PongraczK., PathakD.N., NakamuraT.Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res.1995; 55: 3012–3015.
31.
BarakatR.R., O'ConnorB., BanerjeeD.Mutation of c-Ki-ras in tamoxifen-associated endometrial carcinoma. Proc Annu Meet Am Assoc Cancer Res.1995; 36: A1106.
